Headache Clinical Trial
Official title:
Randomized Controlled Double Masked Two Arm Cross-over Study of Neurolenses in Subjects With Headaches
Verified date | October 2023 |
Source | Neurolens Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Chronic Headaches. It is a Prospective randomized double masked two arm performed on a minimum of 200 to a maximum of 300 subjects identified as symptomatic (HIT-6 questionnaire score equal to or greater than 56) done across 3-15 clinical sites. There are two subgroups: a minimum of 100 in each subgroup (subgroup 1: pre-presbyopic (18-40 years); subgroup 2: presbyopic subjects (41-60 years).
Status | Completed |
Enrollment | 300 |
Est. completion date | May 30, 2022 |
Est. primary completion date | May 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Male or female, and between 18-60 years of age at the time of signing the informed consent. - Best Corrected distance and near acuity are equal to or better than 20/25 Snellen Equivalent in each eye. - Best Corrected distance and near binocular acuity are equal to or better than 20/25 Snellen Equivalent. - Symptomatic as indicated by the HIT-6 questionnaire (Score equal to or greater than 56) - Updated distance spectacle prescription must match the following a. Spherical power inclusive between +4.00D to -8.00D b. Cylinder power no more than -4.00Dcyl c. ADD power i. Subgroup 1: No ADD ii. Subgroup 2: minimum +1.00D ADD - Subjects' eye alignment tests must match the following: a. Successful measurement on the neurolens Measurement Device (Acceptable MQI and a numerical neurolens Value, no Low MQI or Convergence Excess) - Minimum stereo vision of 50 seconds of arc at 16 inches - Capable of committing to the duration of the study. - Willing to comply with study procedures Exclusion Criteria: - Subjects who need a vertical prism. - Previously has worn neurolenses. - Subjects who need a near add less than 1.00D - Use of contact lenses during the study - Lack of binocular vision, including strabismus, amblyopia, or suppression. - Greater than 20 prism diopter of eye misalignment. - Aniseikonia greater than 3.00D spherical equivalent difference between eyes - Prior ocular surgery that in the estimation of the practitioner induces corneal scarring (RK, Corneal Transplant, etc.) or prior surgery involving the extraocular muscles (strabismus surgery). Surgeries that do not affect these parameters such as LASIK, PRK, or pterygium surgery are allowed. - Anterior segment conditions that could obfuscate or obscure reflections from the cornea, or reduce visual acuity, including but not limited to corneal scarring, large pinguecula, pterygium, keratoconus, dermatochalasis, ptosis, exophthalmos or cataract. - Clinical dry eye (defined as tear break-up time of less than 5 seconds) - Intraocular pressures greater than 25 mmHg in either eye or uncontrolled glaucoma - Macular disease, or any posterior segment finding which in the opinion of the investigator is visually and/or clinically significant - Change in acute or prophylactic migraine treatment medication or dosage within the previous two months. - Diabetes with ocular manifestation - Previous head or neck trauma (for instance, car accident, etc.) requiring medical intervention. - Open lesions or sores around the chin or eyes that will make contact with the device and may be subject to contraction or spread of infection. - Physical tremors or muscle spasms that prevent a subject from sitting still. - A history of seizures or seizure disorder. - Women who are pregnant or lactating at the time of the study entry - Mental incapacity that prevents a subject from being able to follow simple instructions such as "look at the target." |
Country | Name | City | State |
---|---|---|---|
United States | Kapperman White and McGarvey | Chattanooga | Tennessee |
United States | The Eye Center | Conyers | Georgia |
United States | Buckeye Family Eye Clinic | Hillsboro | Ohio |
United States | Signature Eye Care | Lincoln | Nebraska |
United States | Preferred Eye Care Center | Mount Pleasant | South Carolina |
United States | Advanced Eyecare Center | Perry | Georgia |
United States | Advanced Vision and Achievement Center | Phoenix | Arizona |
United States | Eyecare of Rigby | Rigby | Idaho |
United States | Eyes for Life | Spokane | Washington |
United States | Springhill Eye Care | Spring Hill | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Neurolens Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Headache Impact Test (HIT-6) questionnaire | Change in headache impact test (HIT-6) with the use of neurolenses compared to control lenses.
The minimum response score for each question is 6 and the maximum is 13. Larger scores would indicate a more symptomatic patient. Larger difference in the cumulative response score between treatment visit and the baseline visit would indicate a greater impact of the treatment. |
30-40 days | |
Secondary | Patients with reduced near point of convergence (NPC) | Change in the headache impact test (HIT-6) score with the use of neurolens compared to control lenses in subjects with reduced Near point of convergence (NPC).
The minimum response score for each question is 6 and the maximum is 13. Larger scores would indicate a more symptomatic patient. Larger difference in the cumulative response score between treatment visit and the baseline visit would indicate a greater impact of the treatment. |
30-40 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03472872 -
A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache
|
Phase 4 | |
Withdrawn |
NCT05410366 -
Safe Harbors in Emergency Medicine, Specific Aim 3
|
||
Withdrawn |
NCT02866084 -
Neuromodulation Treatment of Vestibular Migraines
|
N/A | |
Active, not recruiting |
NCT03537573 -
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
|
N/A | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Not yet recruiting |
NCT04352218 -
Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache
|
Phase 2 | |
Completed |
NCT02734992 -
Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers
|
N/A | |
Completed |
NCT01153789 -
Study of Oculomotor Dysfunction Leading to Children Vertigo
|
N/A | |
Completed |
NCT01327118 -
Prostaglandin F2alpha in a Human Headache Model
|
N/A | |
Not yet recruiting |
NCT00969995 -
Identification of Inflammatory Markers in Migraine Patients
|
N/A | |
Not yet recruiting |
NCT00752921 -
Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache
|
Phase 4 | |
Completed |
NCT00212810 -
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
|
Phase 4 | |
Terminated |
NCT00291395 -
PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00263094 -
An End to the Yom Kippur (and Ramadan) Headache
|
N/A | |
Completed |
NCT00135122 -
Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache
|
Phase 3 | |
Completed |
NCT02475005 -
An Intervention to Improve Adolescent Headache Self-management
|
N/A | |
Completed |
NCT03163901 -
The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury
|
N/A | |
Completed |
NCT01664585 -
Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life
|
N/A | |
Completed |
NCT04632420 -
Evaluation of Headache and Childbirth in a Chronic Pain Population
|
||
Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|